Suberoylanilide hydroxamic acid (SAHA) and cladribine synergistically induce apoptosis in NK‐LGL leukaemia. (4th October 2014)

• Record Type: Journal Article
• Authors: Sun, Xiaoshen; Hasanali, Zainul S.; Chen, Allshine; Zhang, Dianzheng; Liu, Xin; Wang, Hong‐Gang; Feith, David J.; Loughran, Thomas P.; Xu, Kailin
• Is Part Of: British journal of haematology. Volume 168:Number 3(2015:Feb.)
• Page Start: 371
• Page End: 383
• Publication Date: 2014-10-04
• Subjects: Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.13143
• Languages: English
• ISSNs: 0007-1048

Abstract

<abstract abstract-type="main" id="bjh13143-abs-0001"> <title>Summary</title> <p>Natural killer (NK) large granular lymphocyte (LGL) leukaemia features a clonal proliferation of CD3⁻ NK cells that can be classified into either aggressive or chronic categories. The NKL cell line, derived from an aggressive Asian NK cell leukaemia, and patient samples from chronic NK‐LGL leukaemia were used in our study to probe for synergistic efficacy of the epigenetic drugs vorinostat (SAHA) and cladribine in this disease. We demonstrate that histone deacetylases (HDACs) are over‐expressed in both aggressive and chronic NK leukaemia. Administration of the HDAC inhibitor SAHA reduces class I and II HDAC expression and enhances histone acetylation in leukaemic NK cells. <italic>In vitro</italic> combination treatment with SAHA and cladribine dose‐dependently exerts synergistic cytotoxic and apoptotic effects on leukaemic NK cells. Expression profiling of apoptotic regulatory genes suggests that both compounds led to caspase‐dependent apoptosis through activation of intrinsic mitochondrial and extrinsic death receptor pathways. Collectively, these data show that combined epigenetic therapy, using HDAC and DNA methyltransferase inhibitors, may be a promising therapeutic approach for NK‐LGL leukaemia.</p> </abstract>